Clinical Trials
49 trialsNCT01421927 2026-05-22
REVALLO
University Hospital, Bordeaux
Phase 1 Terminated
NCT03173092 2026-05-04
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Takeda
Phase 4 Terminated
NCT05090566 2026-04-24
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Pfizer
Phase 2 Terminated
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT04405167 2025-10-07
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
University of Pennsylvania
Phase 1 Terminated
NCT03376477 2025-08-27
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT03015792 2025-08-17
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Mayo Clinic
Phase 1 Terminated
NCT04892264 2025-05-18
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT04352205 2024-07-01
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Emory University
Phase 2 Terminated
NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
NCT02294357 2023-11-01
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Oncotherapeutics
Phase 2 Terminated
NCT03733691 2023-10-25
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
Oncotherapeutics
Phase 2 Terminated
NCT02906332 2023-08-22
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Hackensack Meridian Health
Phase 2 Terminated
NCT02516696 2023-06-05
BiRd vs Rd
Weill Medical College of Cornell University
Phase 3 Terminated
NCT03411031 2023-03-29
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02077959 2023-01-27
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT01881789 2022-11-14
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Terminated
NCT01555281 2022-07-07
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
Swiss Cancer Institute
Phase 1/2 Terminated
NCT02579863 2021-07-20
KEYNOTE 185
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT02128230 2021-06-22
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
Phase 2 Terminated
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02897830 2020-11-12
IFM2014-03
University Hospital, Toulouse
Phase 2 Terminated
NCT01742793 2020-03-04
RID
Yale University
Phase 1 Terminated
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT03333746 2019-05-30
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT02145598 2019-01-16
GERMAIN
University of Jena
Phase 2/3 Terminated
NCT01303965 2019-01-08
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Indiana University
Phase 1/2 Terminated
NCT01374217 2018-12-10
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00790842 2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2 Terminated
NCT02075021 2018-10-15
rev/abraxane
NYU Langone Health
Phase 1/2 Terminated
NCT02030483 2018-08-22
PD + RD
Weill Medical College of Cornell University
Phase 1 Terminated
NCT02720510 2018-07-24
PANORAMA4
Novartis
Phase 2 Terminated
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT01675141 2018-02-05
Lenalidomide Maintenance Therapy for Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01518465 2017-11-29
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
University of Southern California
Phase 2 Terminated
NCT00843310 2017-07-19
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NYU Langone Health
Phase 2 Terminated
NCT01729338 2017-05-31
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Duke University
Phase 2 Terminated
NCT01750762 2017-04-18
Lenalidomide After Allo Transplant
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT01954784 2017-02-17
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT01947309 2017-01-12
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Celgene
Terminated
NCT01985477 2016-09-14
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00567229 2015-11-20
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00522392 2015-06-26
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
National Cancer Institute (NCI)
Phase 3 Terminated
NCT02353468 2015-03-09
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
University of Colorado, Denver
Phase 2 Terminated
NCT01537861 2015-01-26
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated
NCT01617213 2013-06-21
AMM-2011
University of Virginia
Phase 2 Terminated